drugset / Trial / NCT06539624
Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
Objective: To explore the safety and tolerability of different doses of EXG110 with Fabre disease
Timeline
- Start
- 2024-10-16
- Primary completion
- 2027-04-09
- Completion
- 2027-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EXG110 | Gene therapy (AAV / viral vector) | — | Intravenous |